Skip to content
PipDig
EUR/USD1.08537 +0.24%GBP/USD1.27311 -0.31%USD/JPY156.835 +0.42%XAU/USD4062.31 +0.67%BTC/USD96403.00 +2.16%

Forex News

UZEDY Costs Put at 4688.1 Versus 5724.8 for PP1m

A single source reports UZEDY costs of 4688.1 versus 5724.8 for PP1m, with savings per patient of 1036.7.

PipDig Newsroomอ่านฉบับภาษาไทย
  • UZEDY’s emergency-department visit rate was 22, compared with 27.8 for PP1m.
  • The BD-I treatment-failure figures were 47 for UZEDY and 63 for the other treatment.
  • Against risperidone microspheres, UZEDY’s adherence odds were 3.6 and its discontinuation odds were 0.2.

Cost comparison

The healthcare-cost comparison put UZEDY at 4688.1 and PP1m at 5724.8. Savings per patient were 1036.7.

Unprinted clinical papers, translucent dividers and an unlabelled clear vial rest on a softly lit pale work surface.
UZEDY Costs Put at 4688.1 Versus 5724.8 for PP1m

Treatment data

The BD-I treatment-failure figures were 47 for UZEDY and 63 for the other treatment. UZEDY also reduced emergency-department visits versus risperidone microspheres.

Compared with risperidone microspheres, UZEDY’s adherence odds were 3.6 and its discontinuation odds were 0.2. Its emergency-department visit rate was 22, versus 27.8 for PP1m.

Indications and presentation

UZEDY is indicated for treating schizophrenia in adults and for maintenance treatment of bipolar I disorder.

Teva Pharmaceuticals listed Psych Congress in New Orleans, LA, from September 15 – 19, 2026 as the data presentation location.